All
Navigating Insurance Hurdles and Policy Shortfalls in Breast Cancer Care: Anasuya Gunturi, MD, PhD
July 25th 2025At the recent regional Institute for Value-Based Medicine® event in Boston, Anasuya Gunturi, MD, PhD, Lowell General Hospital, was a panelist for the discussion, “Evolving Breast Cancer Care: Addressing Unmet Needs Across the Patient Journey.”
Read More
Streamlining Breast Cancer Therapy Access for Better Patient Outcomes: Rebecca Chacko, MD
July 23rd 2025Rebecca Chacko, MD, discusses key breast cancer care challenges, including treatment access delays and the importance of open patient communication, as highlighted at the Detroit Institute for Value-Based Medicine session on unmet needs.
Read More
It Take a Village in Cancer Care: A Q&A With David Nguyen, MD
July 23rd 2025David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies
Read More
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Driving Value via Outcomes-Based Pricing and EHR Interoperability: Tyler Sandahl, PharmD
July 7th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for chimeric antigen receptor T-cell and bispecific therapies and the need for improved data sharing in cancer care.
Read More
Clinicians Should Be Able to Rely on Coverage for Category 2B Treatments: Eric Lander, MD
June 24th 2025Eric Lander, MD, discussed the difficulty that clinicians and pharmacists face in getting insurance coverage for category 2B treatments in the National Comprehensive Cancer Network guidelines, which could affect how patients are treated for cancer.
Read More
NCCN Guideline Updates Help Oncologists Navigate ctDNA Use: Eric Lander, MD
June 23rd 2025Circulating tumor DNA (ctDNA) testing changes occur nearly every year, making consistent updates to National Comprehensive Cancer Network (NCCN) guidelines important for clinicians to make decisions on the use of these methods of testing, says Eric Lander, MD.
Read More
Digitizing NCCN Guidelines Could Improve Enrollment in Clinical Trials: Eric Lander, MD
June 19th 2025Making clinical trials easier to find for clinicians and making protocols for entering clinical trials more lenient can help to improve access to clinical trials on a national and local level, explains Eric Lander, MD, of Minnesota Oncology.
Read More
Data Collection Helps the Delivery of Equitable Value-Based Cancer Care: Coral Omene, MD, PhD
June 11th 2025Collecting comprehensive patient data, including social determinants of health, is crucial for equitable value-based cancer care, yet administrative burdens could worsen existing disparities, said Coral Omene, MD, PhD, of Rutgers Cancer Institute and RWJBarnabas Health.
Read More
Pharmacists Essential to Expanding CAR T, Bispecific Access: David Awad, PharmD, BCOP
June 6th 2025David Awad, PharmD, BCOP, says pharmacists play a growing role in managing access, safety, and toxicity for these therapies, ensuring treatments are appropriate and sustainable in real-world oncology practice.
Read More